Net profit at Novo Nordisk has risen 8% to 6.53 billion Danish kroner (just shy of $1 billion) helped by continued strong sales of its diabetes blockbuster Victoza.

Total sales were up 13% to 24.59 billion kroner, while Victoza (liraglutide), Novo’s once-daily human glucagon-like peptide-1 analogue, leapt 24% to 4.01 billion kroner. Like the year before, Victoza still has a 71% market share in the GLP-1 segment, though the company expects this to decline this year as it faces competition with Eli Lilly’s recently-approved Trulicity (dulaglutide).

The firm's stable of modern insulin products, including Levemir (insulin detemir) and NovoRapid (insulin aspart) contributed 11.17 billion kroner, an increase of 10%. As for Novo's biopharmaceuticals business, sales of which climbed 15% to 5.31 billion kroner, NovoSeven (recombinant Factor VIIa) was up 13% to 2.55 billion kroner, while the growth hormone Norditropin rose 9% to 1.81 billion kroner._

Chief executive Lars Rebien Sorensen said that 2014 was “a more challenging year than usual” but he was pleased with Victoza and Levemir. He added that “2015 will be an important year for us” with the first launches of obesity drug Saxenda, a higher dose form of Victoza and Xultophy, a once-daily single injection combination of Tresiba (insulin degludec) and Victoza.